Humabiologics, Inc., a leading innovator in human-derived biomaterials for regenerative medicine, has been selected as one of six companies to receive a groundbreaking inaugural grant from the Piedmont Triad Regenerative Medicine Engine (PTRME). This $2.5 million total investment, funded by the National Science Foundation (NSF), will help propel the Piedmont Triad region’s regenerative medicine industry forward.

Humabiologics will leverage this grant to accelerate its development of human collagen biomanufacturing of the market’s first human collagen matrix for various regenerative medicine applications. Human collagen offers unique properties that hold immense potential to improve healing outcomes and enhance existing regenerative processes. More than 5.7 million Americans suffer from wounds that don’t heal. Expanding biomanufacturing capabilities and regenerative medical applications of Humabiologics’ technology may mean fewer people will suffer such challenges.

“We are honored to be recognized by PTRME for our work in human collagen biomanufacturing,” said Dr. Mohammad Albanna, principal investigator of the grant and Founder & CEO of Humabiologics. “This grant will be instrumental in advancing our clinical translational effort, allowing us to explore the full potential of human collagen as a new class of biomaterial for regenerative medicine beyond research for clinical applications.”

The PTRME, a regional driving force in translating groundbreaking research into real-world regenerative medicine solutions, is located in the Piedmont Triad region. “We are proud to see companies like Humabiologics’ thrive within the PTRME ecosystem. Their efforts highlight our dedication to commercializing research, driving advancements in regenerative medicine, and fostering future manufacturing employment opportunities,” said Tim Bertram, PTRME CEO.

By standardizing processes, scaling manufacturing, and prioritizing sustainability, PTRME is building a robust ecosystem where breakthrough research seamlessly translates into commercialization.

“Having worked alongside Dr. Albanna, it is inspiring to witness his commitment to advancing the field of regenerative medicine. Humabiologics’ project aligns perfectly with the PTRME by driving progress and fueling the economy with the creation of new manufacturing jobs”, said Dr. Anthony Atala, Chief Innovation Officer of the PTRME and Director of Wake Forest Institute of Regenerative Medicine (WFIRM).

Humabiologics will be collaborating with the Wake Forest Institute for Regenerative Medicine (WFIRM) and other members of the PTRME. The company is dedicated to pushing the boundaries of biomaterial science to develop cutting-edge solutions for regenerative medicine, contributing to the development of a thriving regenerative medicine ecosystem in the Piedmont Triad region, and ultimately translating innovation into real-world improvements in patient health and well-being.

About Humabiologics

Humabiologics is a pioneering biotechnology company dedicated to developing and producing high-quality, native human-derived biomaterials for regenerative therapies and tissue engineering applications. The company is committed to advancing the field by providing researchers with innovative and ethically sourced biomaterials that meet the highest standards. The company’s products are used by researchers worldwide to drive advancements in tissue engineering, wound healing and drug discovery. Learn more at www.humabiologics.com.

About The Piedmont Triad Regenerative Medicine Engine

The Piedmont Triad Regenerative Medicine Engine (PTRME), is a National Science Foundation (NSF) funded program awarded to the Wake Forest Institute for Regenerative Medicine, supporting economic development in a 16-county region of central North Carolina through use-inspired research, technology translation, and workforce development at Wake Forest Institute for Regenerative Medicine, Winston-Salem State University, North Carolina Agricultural and Technical State University, and Forsyth Technical Community College. The Engine is a key driver of economic growth in Central North Carolina. By fostering innovation in regenerative medicine, PTRME supports the development of new technologies, creating jobs and attracting investment to the region. The initiative unites academia, industry, and government to accelerate commercialization, provide resources to startups, and train a skilled workforce, thereby cementing the Piedmont Triad as the leading hub in the rapidly growing regenerative medicine industry.

About Wake Forest Institute for Regenerative Medicine

The Wake Forest Institute for Regenerative Medicine is recognized as an international leader in translating scientific discovery into clinical therapies, with many world firsts, including the development and implantation of the first engineered organ in a patient. Over 550 people at the institute, the largest in the world, work on more than 40 different tissues and organs. A number of the basic principles of tissue engineering and regenerative medicine were first developed at the institute. WFIRM researchers have successfully engineered replacement tissues and organs in all four categories – flat structures, tubular tissues, hollow organs and solid organs – and 17 different applications of cell/tissue therapy technologies, such as skin, urethras, cartilage, bladders, muscle, kidney, and vaginal organs, have been successfully used in human patients. The institute, which is part of Wake Forest University, is located in the Innovation Quarter in downtown Winston-Salem, NC, and is driven by the urgent needs of patients. The institute is making a global difference in regenerative medicine through collaborations with over 500 entities and institutions worldwide, through its government, academic and industry partnerships, its start-up entities, and through major initiatives in breakthrough technologies, such as tissue engineering, cell therapies, diagnostics, drug discovery, biomanufacturing, nanotechnology, gene editing and 3D printing. Learn more at WFIRM.org.

Media Contact
Vish Khanna, Humabologics, 1 336-251-2560, vish@producecreative.com, www.humabiologics.com

Read More: https://www.prweb.com/releases/humabiologics-receives-grant-to-advance-human-collagen-biomanufacturing-of-markets-first-human-collagen-matrix-for-regenerative-applications-302343032.html